Seeking Alpha
13 Jun 2026, 16:23 UTC · 13w ago
Verdict
Headline takes no side. We score LYEL +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Lyell Immunopharma expects to release PiNACLE trial data for ronde-cel in the second half of 2026.
So whatPivotal trial data is a primary binary catalyst for biotech valuations and regulatory approval paths.
More positive than 98% of claims this week
Lyell Immunopharma has a cash runway extending through the third quarter of 2027.
So whatSufficient liquidity reduces the immediate risk of dilutive financing and provides stability until major data readouts.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 76% of claims this week
The company's lead candidate, ronde-cel, utilizes dual CD19/CD20 targeting and CD62L+ enrichment to treat relapsed/refractory LBCL.
More positive than 65% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The analyst views the company as undervalued with asymmetric upside and strong efficacy signals for its CAR-T pipeline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
3h ago
−21.3%
Price is moving against the score
$10.63 vs $13.50 close before publication (Jun 12) · not market-adjusted
LYEL chart →
